Inhibikase sees “opportunity” in cardiopulmonary disease for IkT-001Pro
Inhibikase Therapeutics is eying pulmonary arterial hypertension (PAH) as a potential indication for its imatinib alternative IkT-001Pro. In an 18 April …
Clinical trial data analysis and services
Clinical trial data analysis and services: Introduction In the complicated and detailed world of clinical trials, data analysis is one of …
AAN 2024: Pharma Two B’s P2B001 shows promise in early PD
At the American Academy of Neurology (AAN) 2024 Annual Meeting, Pharma Two B presented new safety and tolerability data for …
AAN 2024: Importance of early diagnosis and prompt treatment in SMA
A key theme from the spinal muscular atrophy (SMA) presentations at the American Academy of Neurology (AAN) 2024 Annual Meeting …
AstraZeneca’s Tagrisso maintains momentum in NSCLC with FLAURA2 results
Lung cancer is the leading cause of cancer death around the world, with an estimated 2.2 million new cases and …
D2M Biotherapeutics doses first subject in solid tumour treatment trial
D2M Biotherapeutics has dosed the first subject in a Phase I clinical trial of DM919 for the potential treatment of …
Philippine FDA grants clearance for YS Biopharma’s hepatitis B vaccine trial
The Philippine Food and Drug Administration (PFDA) has granted clinical trial approval for YS Biopharma's YS-HBV-002, an immunotherapeutic vaccine aimed …
Smith+Nephew touts study supporting pressure wound dressing
Medical technology company, Smith+Nephew ,has announced the publication of a study highlighting that its ALLEVYN LIFE foam dressing shows a …
Barinthus’ HPV therapy meets primary endpoint in Phase I/II trial
The UK-based Barinthus Biotherapeutics (formerly Vaccitech) has released topline data from its Phase Ib/II APOLLO trial for its human papillomavirus …
AbbVie reports findings from giant cell arteritis therapy trial
AbbVie has revealed positive top-line outcomes from the first period of the Phase III SELECT-GCA study of upadacitinib (RINVOQ; 15mg, …
Cerevel reports positive data from Phase III Parkinson’s treatment trial
Cerevel Therapeutics has reported positive topline results from its Phase III TEMPO-3 clinical trial evaluating a once-a-day dose of tavapadon …
Leading cybersecurity companies in clinical trials
Clinical trial software is vulnerable to breaches and ransomware attacks, as clinical trials become more decentralised and incorporate the use …
AAN 2024: Four-year follow-up of Roche’s PRX-002 encouraging for Parkinson’s disease
There are currently no marketed disease-modifying therapies (DMTs) for Parkinson’s disease (PD). Key opinion leaders (KOLs) previously interviewed by GlobalData, …
AAN 2024: new pooled data highlights efficacy of Axsome Therapeutics’s AXS-07
On 15 April, at the American Academy of Neurology (AAN) 2024, Axsome Therapeutics presented new pooled data from two Phase …
gaitQ and machineMD secure $1m to kickstart Parkinson’s movement study
Oxford-based start-up gaitQ and Swiss medical device company machineMD have been awarded a $1m grant from InnovateUK and Innosuisse to …